Cabometyx® In Combination With Nivolumab Shows Durable Survival Benefits At Over Three-Years' Follow-Up In First-Line Advanced Renal Cell Carcinoma

Prensa/medios de comunicación

Período13 feb. 2023

Cobertura de los medios

1

Cobertura de los medios

  • NombreCabometyx® In Combination With Nivolumab Shows Durable Survival Benefits At Over Three-Years' Follow-Up In First-Line Advanced Renal Cell Carcinoma
    Nombre/canal del medio de comunicaciónMENAFN -Press Releases (English)
    País/TerritorioJordania
    Fecha13/02/23
    PersonasMauricio Burotto